Evaluating Ovid Therapeutics: Insights From 6 Financial Analysts
Evaluating Ovid Therapeutics: Insights From 6 Financial Analysts
評估ovid therapeutics：來自6位金融分析師的見解
In the latest quarter, 6 analysts provided ratings for Ovid Therapeutics (NASDAQ:OVID), showcasing a mix of bullish and bearish perspectives.
在最新的季度中，6位分析師就Ovid Therapeutics (NASDAQ:OVID)提供了評級，呈現出看好和看淡的態度。
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
下表提供了他們最近的評級快照，展示了情緒在過去30天中的演變情況，並將其與之前的月份進行比較。
Analysts have recently evaluated Ovid Therapeutics and provided 12-month price targets. The average target is $6.92, accompanied by a high estimate of $9.00 and a low estimate of $3.00. Experiencing a 5.59% decline, the current average is now lower than the previous average price target of $7.33.
分析師最近對Ovid Therapeutics進行了評估，並提供了12個月的價格目標。平均目標爲6.92美元，最高預估爲9.00美元，最低爲3.00美元。經歷了5.59%的下跌，當前平均價位比先前的平均目標價格7.33美元低。
Investigating Analyst Ratings: An Elaborate Study
分析師評級的調查：一項詳盡的研究
The perception of Ovid Therapeutics by...
通過最近的分...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。